原文 Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting 出處 GlobeNewswire 連結 https://twitter.com/aimedadviser/status/1647779694530686978 序號 3318